Biosimilars are the fastest-growing class of therapeutic products across the globe. Biosimilars are biologics that serves as interchangeable products offering additional treatment options to a branded drug counterpart, potentially reducing the cost of the prescribed biologics. The biosimilar therapies have been for chronic disease management and supportive care since a few years, however the use of these biosimilars are expected to be applied soon for treatment of various types of cancers referred to as oncology biosimilars.
The "Global Oncology Biosimilars Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of the oncology biosimilars market with detailed market segmentation by product, cancer type, and geography. The report provides key statistics on the market status of the leading oncology biosimilars market players and offers key trends and opportunities in the market.
- Based on product, the global oncology biosimilars market is segmented into monoclonal antibodies, immunomodulators, other products.
- On the basis of cancer type, the market is segmented into lung cancer, colorectal cancer, cervical cancer, breast cancer, stomach cancer, brain cancer, others.
- Rise in the prevalence of cancer
- Growing demand for innovative therapies
- Loss of patent exclusivity of the leading biologic drugs
- Stringent Regulatory Process
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The Oncology Biosimilars market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.
The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the marketduring the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the market in these regions.
IMPACT OF COVID-19 ON ONCOLOGY BIOSIMILARS MARKET
The COVID-19 pandemic is imposing great challenges on the oncology biosimilars market and pharmaceutical companies focused on biosimilar development. The delay in the FDA approval of non-COVID therapeutics has hampered the product approvals and launches. Also, many clinical trials have been postponed minimizing the infection of COVID-19 situation and, most of the pipeline products are exhibiting a slow pace of research and development activities. Thus, COVID-19 is negatively impacting the growth of the market.
The report covers key developments in the oncology biosimilars market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the marketwere acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market payers from oncology biosimilars market are anticipated to lucrative growth opportunities in the future with the rising demand for Oncology Biosimilars market in the global market.
The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the oncology biosimilars market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.
- Celltrion Inc.
- Dr. Reddy's Laboratories Ltd.
- Amgen Inc.
- Intas Pharmaceuticals Ltd.
- Pfizer Inc.
- Sandoz International GmbH (A Novartis Division)
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V.
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.